Triamcinolone and Bevacizumab as Adjunctive Therapies to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Table 2

Changes in the number of active new vessels (No. NV), best corrected visual acuity (BCVA), and central macular thickness (CMT) in the different groups before and after treatments, expressed as mean (SD).

	Baseline			1 month		2 months			6 months
	No. NV	BCVA	CMT	BCVA	CMT	No. NV	BCVA	CMT	No. NV	BCVA	CMT
PRP group	3.45 (2.0)	67.35 (22.5)	342.05 (118.7)	64.25 (21.60)	374.75 (141.6)	2.28 (2.2)	65.68 (20.65)	347.75 (101.7)	2.5 (2.1)	64.88 (21.74)	370.2 (106.1)
				𝑃=0.183	𝑃=0.124	𝑃=0.049	𝑃=0.521	𝑃=0.402	𝑃=0.064	𝑃=0.055	𝑃=0.129
IVB group	4.79 (4.4)	75.53 (18.99)	309.05 (89.9)	74.88 (16.49)	313.94 (85.9)	0.05	75.32 (15.15)	314.58 (104.2)	1.11 (1)	74.74 (17.14)	354.3 (133.4)
				𝑃=0.623	𝑃=0.902	𝑃=0.001	𝑃=0.923	𝑃=0.671	𝑃=0.002	𝑃=0.628	𝑃=0.032
IVT group	4.35 (3.3)	76.65 (9.99)	323.09 (157.3)	74.47 (9.02)	258.79 (69.7)	1.25 (1.9)	74.75 (11.67)	279.75 (89.6)	1.11 (1.4)	72.72 (12.69)	310.9 (110.1)
				𝑃=0.278	𝑃=0.02	𝑃=0.001	𝑃=0.191	𝑃=0.134	𝑃=0.001	𝑃=0.011	𝑃=0.857

The Student’s t test was used to compare the changes in outcomes to the baseline for the three groups. BCVA, best-corrected visual acuity; CMT, central macular thickness; No. NV: number of new vessels; IVB: intravitreal bevacizumab; IVT: intravitreal triamcinolone; PRP: panretinal photocoagulation; SD: standard deviation.